Clinical Data for LiquidMD

Latest Study Results: July 15, 2009

Health Enhancement Products Announces Positive Preliminary Analysis of Wayne State University Study

Initial Results Show PAZ Organic Compounds Significantly Reduce LDL (Bad) Cholesterol and Significantly Improve HDL (Good) Cholesterol

SCOTTSDALE, Ariz., July 15, 2009 (GLOBE NEWSWIRE) -- Health Enhancement Products, Inc. (OTCBB:HEPI - News) today announced preliminary results of its study to confirm the efficacy of the ProAlgaZyme (PAZ) bioactive compound in managing LDL and HDL cholesterol levels. The Company awarded a grant to the Department of Nutrition and Food Science of Wayne State University on March 30, 2009. Wayne State University (WSU) ranks among the nation's top 50 public universities engaged in basic and applied biomedical research by the National Science Foundation.

The Wayne State University study was able to confirm that the PAZ organic compound was found to reduce LDL cholesterol levels from 131.7mg/dL to 79.57mg/dL and improve HDL cholesterol from 105.27mg/dL to 138.67mg/dL in test animal subjects. Upon completion of the study, Wayne State will publish a scientific paper describing the final results, as well as the means and methods employed, to be authored by the principal investigator, Smiti Gupta, Ph.D., assistant professor of Nutrition and Food Science at WSU.

The cholesterol findings are initial results of a larger study, which also includes investigating the effect of PAZ organic compounds on the management of generalized inflammation. Those results are pending and will be released as they are completed by WSU.

Dr. Gupta commented, "The results show a statistically significant decrease in total plasma cholesterol (TC) and LDL. What was even more interesting was the statistically significant increase in HDL, leading to a marked improvement in the TC/HDL ratio. While these initial findings in the hamster model are exciting and promising, further studies are needed, some of which are currently underway."

"These results mark a turning point in our company's history as it confirms prior studies and represents an important step forward in identifying the bioactive agents in our PAZ organic compound. Once the study is completed, subject to the identification of the active molecules, we will begin the process of developing specific commercial applications of the bioactive compounds so that they can be introduced into branded functional foods, supplements, sports drinks and composite nutraceuticals," states John Gorman, the company's sales director. "We are particularly struck by the ability of the PAZ compound to significantly increase HDL levels. This result is considered unique because exercise is considered to be the single best option to raise HDL levels. We will update the investment community with additional benefits as more results become available."

Our publication of a clinical trial investigating the effects of LiquidMD (ProAlgaZyme) on Metabolic Syndrome and markers of cardiovascular health.

Click to read summary:
http://www.lipidworld.com/content/6/1/20

You may also download the full article as a PDF file with color graphs:
http://www.lipidworld.com/content/pdf/1476-511x-6-20.pdf 

The article was published in Lipids in Health and Disease,
a free open-access journal in the BioMed Central network of journals.

LiquidMD (ProAlgaZyme) (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving
cardiovascular risk factors over a course of 10 weeks.

 *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.